We have placed cookies on your computer to help make this website better. We use an Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking (e.g. deny use/opt-out). Read our policy

Accept Cookies

Palexia®

This website is intended for patients prescribed with Palexia® PR or Palexia® IR.

Access information for Healthcare Professionals

What is Palexia®?

For patients prescribed Palexia® PR (tapentadol prolonged release) for severe chronic pain and Palexia® IR (tapentadol immediate release) for moderate to severe acute pain.1,2

Developed by Grünenthal, this website is a growing resource of information where you can learn more about your treatment and your condition.

This website contains relevant information and support resources around Palexia® PR (for severe chronic pain) and Palexia® IR (for moderate to severe acute pain). Make sure you explore the section that is most relevant to you. It will help you to understand more about your pain medication, how it works and what you should expect from your treatment.

However, your treatment should always be discussed with your doctor or pharmacist and this website is not a replacement for the patient information leaflet (PIL) or your doctor/patient relationship.

Palexia<sup>®</sup> PR

About Palexia® PR

Palexia® PR (for severe chronic pain) is the brand name for tapentadol prolonged release, which is a strong pain medication. Palexia® PR is used for the treatment of severe chronic pain in adults that can only be adequately managed with opioid analgesics.[ref]

... More about Palexia® PR
Palexia<sup>®</sup> IR

About Palexia® IR

Palexia® IR (for moderate to severe acute pain) is the brand name of tapentadol immediate release, which is a strong pain medication. Palexia® IR is used for the relief of moderate to severe acute pain in adults which can only be adequately managed with opioid analgesics.3

... More about Palexia® IR
  • References

    1. Palexia® PR SmPC, July 2016.

    2. Mehra M et al. The burden of chronic low back pain with and without a neuropathic component: a healthcare resource use and cost analysis. J Med Econ. 2012; 15(2):245-52.

    3. Baron R et al. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Trial. Pain Practice 2016; 16(5):600-619.